Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases
Research and Practice in Thrombosis and Haemostasis · 2023-07 · 7 (5) · 100201
DOI: 10.1016/j.rpth.2023.100201 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2023-07. Verfasst von Sophie Melicine und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris, Paris, France. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca, Boehringer Ingelheim.
Abstract (Originalsprache)
Idarucizumab is a humanized monoclonal antibody fragment targeting dabigatran with a very high affinity approximately 300 times greater than the affinity of dabigatran for thrombin, thus potently and specifically neutralizing dabigatran and its anticoagulant effect [1,2]. Accordingly, idarucizumab is the specific antidote used for dabigatran reversal in patients with life-threatening/uncontrolled bleeding or those requiring an urgent or invasive procedure. In phase III of the Reversal of Dabigatran Anticoagulant Effect With Idarucizumab (RE-VERSE AD) trial [3], 2 consecutive doses of 2.5 g of idarucizumab within 15 minutes showed a median maximum percent reversal of 100% after 4 hours.
Autor:innen und Institutionen
- Hematology Department, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris, Paris, France.
- Unité d'hémostase vasculaire, UNIROUEN, INSERM U1096, Normandie Univ, Hôpital Universitaire Rouen, Rouen, France.
- Laboratoire d'Hématologie, Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Paris, France.
- Université Paris Cité; Université Sorbonne Paris Nord, INSERM U1148, LVTS, Paris, France.
- Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
- Faculty of Health, Aarhus University, Aarhus, Denmark.
Förderung
- AstraZeneca
- Boehringer Ingelheim
Zitieren
APA
Melicine, S., Billoir, P., Faille, D., Grove, E. L., Lê, M. P., Ajzenberg, N., Smadja, D. M., & Gendron, N. (2023). Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases. Research and Practice in Thrombosis and Haemostasis, 7(5), 100201. https://doi.org/10.1016/j.rpth.2023.100201
Vancouver
Melicine S, Billoir P, Faille D, Grove EL, Lê MP, Ajzenberg N, et al. Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases. Research and Practice in Thrombosis and Haemostasis. 2023;7(5):100201. doi:10.1016/j.rpth.2023.100201
BibTeX
@article{Melicine2023,
author = {Melicine, Sophie and Billoir, Paul and Faille, Dorothée and Grove, Erik Lerkevang and Lê, Minh P and Ajzenberg, Nadine and Smadja, David M and Gendron, Nicolas},
title = {Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2023},
volume = {7},
number = {5},
pages = {100201},
doi = {10.1016/j.rpth.2023.100201}
}
EUVIMED